Laboratory measures of platelet aggregate formation are used as a key component in the assessment of platelet function defects. The "gold standard" diagnostic test for assessing in vitro platelet function is light transmission aggregometry (LTA), developed by Born in the 1960s, 4 in which the change in optical density of a rapidly stirred sample of citrated platelet-rich plasma (PRP) is measured by a photometer. Upon addition of a panel of physiologically relevant agonists, the platelets change shape resulting in a transient, small decrease in light transmission followed by an increase as the platelets aggregate in a fibrinogen-dependent manner. Changes to the normal patterns of response to the agonist panel can identify specific platelet defects and provide diagnostically relevant information about a patient's platelet function. 5 Despite the long history of LTA for clinical laboratory diagnoses, it is only recently that standardization of LTA testing through guideline development has resulted in recommendations on the preparation of PRP; agonist choice and concentrations; interpretation of results; and ancillary testing. Since
2008, four guidelines have been published, with the goal of improv-
ing the quality of LTA in clinical laboratories. [5] [6] [7] [8] LTA, however, has inherent disadvantages that cannot be overcome by standardization.
These include the time required for preparation and analysis of PRP samples; the potential for sample manipulation required for PRP preparation to cause ex vivo platelet activation and spurious test results; and the volume of blood required for testing a full agonist panel (up to 30 mL), which makes testing prohibitive in infants and young children. 9 Not surprisingly, a recent survey has shown that LTA is only available in specialized hemostasis laboratories due to the requirements of sample preparation and test result interpretation. 10 Because of these disadvantages, alternative platelet function testing methods have been developed, but have not replaced LTA in most clinical laboratories, to date. 11, 12 Multiple electrode aggregometry (MEA) measures platelet aggregation in whole blood by electrical impedance between two electrodes as platelets adhere and aggregate on the electrodes in response to agonist stimulation. The aggregation response is expressed as the area under the impedance curves determined over time (AUC). the variations in platelet count and hematocrit inherent in using whole blood, 11 and the potential for ADP released from red blood cells to induce aggregation in the absence of agonists. Recognizing and adjusting for this "spontaneous" aggregation is required when interpreting the results of MEA testing.
13,14
Agonist responsiveness has been reported to differ between LTA and MEA, but direct comparison studies of the two methodologies have been few. 19, 20 MEA can identify patients with severe platelet function abnormalities such as Glanzmann thrombasthenia, 20,21 but may be less sensitive than LTA to mild/moderate platelet aggregation abnormalities. 11, 19, 20 Most clinical studies have used the Multiplate ® manufacturer-recommended concentrations of ADP, collagen, arachidonic acid, and thrombin receptor-activating peptide (TRAP), and few studies have been done to determine optimal agonist concentrations for investigation of aggregation abnormalities. 13 The goal of the present study was to directly compare aggregation responses to threshold concentrations of agonists, using LTA and MEA, in patients referred for laboratory evaluation of mucocutaneous bleeding, and to determine whether MEA could be a viable substitute for LTA in the investigation of these patients.
| MATERIAL S AND ME THODS

| Subjects
All participants or their parents gave written informed consent (as approved by the University of Manitoba Research Ethics Board)
prior to blood collection. 
| Normal controls
| Patients
Between No patient had an existing diagnosis of a hemostatic abnormality.
Patients completed a medication questionnaire at the time of blood collection.
| Reagents
ADP, collagen, and arachidonic acid were purchased from Helena 
| Light transmission aggregometry
| Sample preparation
Platelet-rich plasma was prepared by centrifugation of citrated whole blood at 200 g for 10 minutes at room temperature. Platelet counts of PRP were obtained using a Sysmex XE-5000 cell analyzer (Sysmex America, Mundelein, IL, USA). Platelet-poor plasma (PPP)
was prepared by centrifugation of PRP at 1000 g for 10 minutes.
PRP platelet counts were adjusted to 250 × 10 9 /L by the addition of autologous PPP. Samples were maintained at room temperature until testing.
| Platelet aggregation testing
Platelet aggregation assays were performed using an AggRam Platelet Aggregometer (Model 700, Helena Laboratories) using 300 μL stirred at 600 rpm at 37°C and stirred for 1 minute before the addition of agonist. Parameters for response were adjusted to 100% using PPP and 0% using PRP from each participant. Agonist concentrations in use for clinical laboratory testing were used in this study, representing previously identified threshold concentrations in normal controls. All concentrations had established reference intervals developed from the evaluation of at least 40 healthy, medication-free adults. Agonists were added to the PRP, and platelet aggregation was monitored for 5 minutes by aggregometer tracings.
Final concentrations of agonists were ADP (2.5 μmol/L), arachidonic acid (1.5 mmol/L), collagen (1.25 μg/mL), TRAP (20 μmol/L). The maximum percent aggregation was recorded. The lower limit cutoffs of reference intervals for the agonists were ADP, 44%; arachidonic acid, 75%; collagen, 72%; TRAP, 69%.
| Multiple electrode aggregometry
Whole blood aggregometry was performed using the Multiplate ® analyzer (Roche Diagnostics), utilizing disposable test cells in five channels for parallel testing. In each test cell, 300 μL of whole blood was diluted with 300 μL of pre-warmed 0.9% saline and incubated for 3 minutes at 37°C before the addition of agonist. Threshold concentrations for each agonist used in this study were determined by testing the response to increasing concentrations of each agonist, in healthy adult volunteers. For each agonist, the highest concentration tested was the concentration recommended by the manufacturer. 
| Statistical analysis
For preliminary MEA studies of volunteer control subjects, data dis- Twenty-nine patients (30%) had at least one abnormal agonist response by LTA (Table 1) ; 15 of these patients (15% of all patients) had >1 abnormal agonist response. Thirty-six patients (36%) had at least one abnormal agonist response by MEA; 27 of these (27% of all patients) had >1 abnormal agonist response.
Twenty-four patients were between the ages of 2 years and 10 years of age. Of these 24 patients, 6 (25%) had at least one abnormal agonist response by LTA; 3 (12.5%) patients had >1 abnormal agonist response. Eight patients (33%) had at least one abnormal agonist response by MEA; 5 (21%) had >1 abnormal agonist response.
These results were not significantly different from the full patient cohort.
| Comparison of LTA and MEA
The concordance between LTA and MEA aggregation results for each agonist is shown in Concordance for overall response to agonists was 85% (Table 1) , with 59 patients having no abnormal response to any agonist using either method; 25 having at least one abnormal response with each method (κ = 0.66).
Sensitivity, specificity and predictive values for each agonist are shown in Table 2 . PPVs were low for all agonists. Abnormal aggregation responses by MEA testing did not predict abnormal aggregation responses identified by LTA. The NPVs, however, were >0.9 for all agonists. Of the 63 patients that had a normal response to all agonists using MEA, 59 (94%) had normal responses to all four agonists using LTA, and four patients had an isolated decreased LTA response to ADP at a concentration of 2.5 μmol/L. These four patients had normal LTA responses to ADP when tested at a higher concentration (5 μmol/L) (data not shown).
| D ISCUSS I ON
MEA testing for clinical evaluation of platelet aggregation has advantages over the "gold standard" LTA including smaller blood volumes, less sample manipulation, and less complex testing. There is less information about its utility for the diagnosis of platelet ag- TA B L E 1 Concordance between light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA) for agonists: ADP, arachidonic acid, collagen, and TRAP (n = 99) in response to agonists (data not shown). Sodium heparin was subsequently used as the anticoagulant for collection of samples for
MEA.
Agonist concentrations for MEA recommended by the manufacturer for ADP, arachidonic acid, collagen, and TRAP are maximal doses ( Figure 1 ) and are likely to be most useful where the goal of testing is to assess the effect of antiplatelet therapy. We hypothesized that identification of threshold concentrations for agonists had the potential for improving sensitivity to mild/moderate platelet aggregation abnormalities, similar to LTA, where use of threshold concentrations is recommended. 5, 8, 24 The agonist concentrations used for MEA in the present study are, therefore, lower than concentrations used in previous studies of normal controls or patients. 15, [19] [20] [21] 25 The threshold concentrations for ADP, collagen, and TRAP used in the present study are similar to those identified by Toth et al, 13 although the anticoagulant used for the present study was different (sodium heparin rather than citrate or hirudin). Reference intervals were developed for these agonist concentrations using healthy control subjects, with cutoff values determined as two SDs below the mean. Agonist concentrations were not the same for MEA and LTA; threshold concentrations for each agonist/method pair were used.
Comparison of MEA and LTA results was examined for each agonist in the 99 patient samples (Table 1, Figure 3 ). Concordance varied depending on the agonist, but MEA results did not adequately predict aggregation abnormalities identified by LTA for any agonist, as demonstrated by the PPVs ( Table 2) . In this study, using threshold agonist concentrations did not clearly improve the PPV of MEA agonist responses vis. a vis. LTA agonist responses.
More useful were the NPVs, which were greater than 90%
for each agonist at threshold concentration ( not have gone on to testing with LTA, while 36% of patients with one or more abnormal MEA result(s) would have required further testing with LTA.
This study included 24 children, age ≤10 years (25% of the study population). This is the age-group for which blood-sampling volumes can be most limiting and therefore a population of particular interest. Although the sample size did not allow calculation of the sensitivity and specificity for MEA vs LTA for this subgroup, in comparison with the whole, the frequency of abnormal aggregation responses for both LTA and MEA was not different than for the patients > 10 years of age.
As no patient had a confirmed diagnosis of a platelet function disorder at enrollment, the purpose of this study was not to identify the utility of either method in the identification of specific platelet function abnormalities, as described by Al Ghaithi et al. 19 In contrast to Al Ghaithi's study, we found more patient samples with abnormal MEA responses than with abnormal LTA responses, including patients who had more than one abnormal agonist response: 28%
(MEA) vs 15% (LTA). The contrast between the two studies may relate to differences in the study populations and was likely influenced by differences in the anticoagulant used for MEA sample collection and the agonist concentrations used for MEA testing (lower in the present study). Similarly, in a recent retrospective study of children investigated for clinical bleeding, MEA was found to be insensitive to platelet disorders identified by LTA, but the MEA agonist concentrations in that study were more than 10-fold higher than in the present study, 25 making comparisons difficult.
The limitation of the study is that detailed clinical information about bleeding outcomes was not available for the patients. Future correlative studies of clinical bleeding with the results of MEA and LTA testing will help to identify whether there is a difference in the sensitivity of the methodologies to mucocutaneous bleeding.
The purpose of this study was to determine whether MEA could substitute for LTA in the evaluation of platelet aggregation for the diagnosis of platelet aggregation disorders. MEA was not adequately predictive of specific abnormal LTA agonist responses to replace LTA testing. LTA has the advantage of dynamic aggregation tracings that demonstrate features in addition to maximum aggregation, including platelet shape change, primary and secondary waves of aggregation, lag and slope of the aggregation curves. 26, 27 Either method would require ancillary studies using lumi-aggregometry for the diagnosis or confirmation of granule secretion defects. 24 Finally, LTA has been the subject of rigorous review and the development of guidelines that direct sample preparation, agonist choice and concentrations, and the interpretation test results. 5, 6, 8 Experience in the use of MEA for screening or diagnosis for platelet aggregation disorders is still limited, and this study highlights that the identification of agonist concentrations that optimize the utility of the Multiplate ® analyzer still requires refinement.
In summary, abnormalities of MEA agonist responses did not adequately predict LTA agonist responses for ADP, arachidonic acid, collagen, or TRAP at the agonist concentrations chosen for this study. However, MEA showed promise as a screening test, particularly in settings where sample volume or testing expertise is limited, to differentiate between patients who are unlikely to have a platelet aggregation disorder and those who require a more complete laboratory evaluation of platelet function.
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